FY2025 EPS Estimates for LXEO Decreased by Chardan Capital

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Investment analysts at Chardan Capital decreased their FY2025 EPS estimates for Lexeo Therapeutics in a report issued on Tuesday, March 25th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings of ($3.10) per share for the year, down from their previous forecast of ($2.30). Chardan Capital has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09.

Several other brokerages have also commented on LXEO. HC Wainwright reissued a “buy” rating and set a $23.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday. Royal Bank of Canada cut their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Leerink Partners lowered their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Monday. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $22.80.

Lexeo Therapeutics Trading Up 3.0 %

LXEO opened at $4.11 on Friday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 52 week low of $2.32 and a 52 week high of $19.50. The stock has a market cap of $135.90 million, a PE ratio of -1.30 and a beta of 3.85. The business has a 50 day moving average of $4.07 and a 200-day moving average of $6.63.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its holdings in Lexeo Therapeutics by 107.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock worth $577,000 after acquiring an additional 33,013 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Lexeo Therapeutics by 121.5% during the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock valued at $129,000 after purchasing an additional 7,803 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Lexeo Therapeutics by 1.2% during the third quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock valued at $7,684,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Verition Fund Management LLC boosted its position in shares of Lexeo Therapeutics by 84.5% during the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after buying an additional 355,928 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.